FDA approves aflibercept for diabetic retinopathy
- Posted on: May 15 2019
- Leave a response
Aflibercept is now an approved treatment for all stages of diabetic retinopathy (DR), making it the only anti-VEGF agent with two dosing options for DR.
Source: AAO
Posted in: Uncategorized
